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The galactose ring in the title compound, C21H24O11, has a
chair conformation with the substituted benzene ring
occupying an equatorial position. The crystal packing features
C—H   O interactions that lead to the formation of supra-
molecular layers in the ab plane.
Related literature
For the synthesis, see: Benassi et al. (2007); Patil et al. (2008).
For the biological activity of related structures, see: Zheng et
al. (2010). For the structure of the isomeric allopyranoside and
glucopyranoside derivatives, see: Ye et al. (2009); Heidelberg







a = 11.8358 (4) A ˚
b = 5.6664 (2) A ˚
c = 17.5079 (6) A ˚
  = 109.616 (4) 
V = 1106.05 (7) A ˚ 3
Z =2
Mo K  radiation
  = 0.11 mm
 1
T = 100 K
0.25   0.20   0.05 mm
Data collection
Agilent Supernova Dual
diffractometer with an Atlas
detector
Absorption correction: multi-scan
(CrysAlis PRO; Agilent, 2010)
Tmin = 0.596, Tmax = 1.000
10396 measured reﬂections
2768 independent reﬂections













 max = 0.21 e A ˚  3
 min =  0.21 e A ˚  3
Table 1
Hydrogen-bond geometry (A ˚ ,  ).
D—H   AD —H H   AD    AD —H   A
C3—H3   O9
i 1.00 2.39 3.199 (3) 137
C5—H5   O9
i 1.00 2.45 3.268 (3) 139
C10—H10b   O3
ii 0.98 2.46 3.307 (3) 145
C12—H12b   O5
iii 0.98 2.57 3.548 (3) 172
C14—H14c   O11
iv 0.98 2.50 3.415 (4) 155
Symmetry codes: (i) x;y   1;z; (ii) x;y þ 1;z; (iii)  x þ 2;y þ 1
2; z þ 1; (iv)
x þ 1;y;z.
Data collection: CrysAlis PRO (Agilent, 2010); cell reﬁnement:
CrysAlis PRO; data reduction: CrysAlis PRO; program(s) used to
solve structure: SHELXS97 (Sheldrick, 2008); program(s) used to
reﬁne structure: SHELXL97 (Sheldrick, 2008); molecular graphics:
ORTEP-3 (Farrugia, 1997) and DIAMOND (Brandenburg, 2006);
software used to prepare material for publication: publCIF (Westrip,
2010).
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Supplementary data and ﬁgures for this paper are available from the
IUCr electronic archives (Reference: EZ2236).
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